Nothing Special   »   [go: up one dir, main page]

EP1324776B2 - Formulations de proteine concentrees a viscosite reduite - Google Patents

Formulations de proteine concentrees a viscosite reduite Download PDF

Info

Publication number
EP1324776B2
EP1324776B2 EP01981824.4A EP01981824A EP1324776B2 EP 1324776 B2 EP1324776 B2 EP 1324776B2 EP 01981824 A EP01981824 A EP 01981824A EP 1324776 B2 EP1324776 B2 EP 1324776B2
Authority
EP
European Patent Office
Prior art keywords
formulation
antibody
immunoglobulin
antibodies
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01981824.4A
Other languages
German (de)
English (en)
Other versions
EP1324776A2 (fr
EP1324776B1 (fr
Inventor
Jun Liu
Steven J. Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Genentech Inc
Original Assignee
Novartis AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1324776(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Genentech Inc filed Critical Novartis AG
Priority to SI200130952T priority Critical patent/SI1324776T2/en
Priority to EP09010433.2A priority patent/EP2116265B1/fr
Publication of EP1324776A2 publication Critical patent/EP1324776A2/fr
Application granted granted Critical
Publication of EP1324776B1 publication Critical patent/EP1324776B1/fr
Priority to CY20091101163T priority patent/CY1110547T1/el
Publication of EP1324776B2 publication Critical patent/EP1324776B2/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/80—Elimination or reduction of contamination by undersired ferments, e.g. aseptic cultivation

Definitions

  • This invention pertains to concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration.
  • the invention further concerns a method of reducing viscosity of concentrated protein formulations.
  • Proteins tend to form viscous solutions at high concentration because of their macromolecular nature and potential for intermolecular interactions. Moreover, many proteins are often lyophilized in the presence of large amounts of lyoprotectants, such as sugar to maintain their stability. The sugar can enhance the intermolecular interactions and increase the viscosity. Highly viscous formulations are difficult to manufacture, draw into a syringe and inject subcutaneously. The use of force in manipulating the viscous formulations leads to excessive frothing, and the resultant detergent-like action of froth has the potential to denature and inactivate the therapeutically active protein. Moreover, viscous solution increases the back-pressure during UF/DF process and makes recovery of protein difficult. This can result in considerable loss of protein product. Satisfactory solution of this problem is lacking in the prior art. Therefore, there is a need to develop a method of reducing the viscosity of a formulation containing high concentration of protein.
  • Stable isotonic lyophilized protein formulations are disclosed in PCT publication WO 97/04801, published on February 13, 1997 .
  • the disclosed lyophilized formulations can be reconstituted to generate high protein-concentration liquid formulations without apparent loss of stability.
  • the potential issues associated with the high viscosity of the reconstituted formulations are not addressed.
  • tissue damage was observed only when hypertonic solution of 1300 mOsmol/Kg ( ⁇ 650 mM NaCl) or higher was administered subcutaneously or intramuscularly to experimental animals. As a result, formulations which are slightly hypertonic, or outside of the physiological pH range do not appear to present a risk of tissue damage at the site of administration.
  • EP 0 661060 describes concentrated immunoglobulin preparations having low osmolarity and low viscosity.
  • WO 97/04-801 describes stable isotonic lyophilized antibody formulations.
  • the present invention is directed to providing a high concentration immunoglobulin formulation with reduced viscosity, which is easy to handle and is suitable for subcutaneous administration.
  • the present invention is further directed to providing a method of reducing viscosity of concentrated immunoglobulin formulations.
  • the present invention concerns a method of lowering the viscosity of concentrated immunoglobulin composition by: increasing the total ionic strength of the formulation through the addition of salts or buffer components as defined in the claims without significantly compromising stability or biological activity. Accordingly, the invention concerns methods and means for reducing the viscosity of concentrated immunoglobulin formulations, primarily to ensure easy manipulation before and during administration to a patient.
  • the present invention provides a stable liquid formulation comprising an immunoglobulin in an amount of at least about 80 mg/ml and a salt and/or a buffer in an amount of at least 100 mM, and having a kinematic viscosity of about 50 mm2/s or less at 25°C, wherein the immunoglobulin is the antibody rhuMAb-E25, rhuMAb-E26, or rhuMAb-E27, and wherein said salt is not sodium chloride, as set out in the claims.
  • the salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) or base forming metals and amines.
  • the salts and/or buffers may be derived from amino acids.
  • the salts are chosen from the group consisting of arginine hydrochloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, zinc chloride and sodium acetate.
  • the salts or buffers are monovalent.
  • the formulation contains the above salt or buffer components in an amount of about 100-200 mM, and has a viscosity of about 2 to 30 mm 2 /s.
  • the formulation is hypertonic.
  • the formulation may further comprise a surfactant such as polysorbate.
  • the invention also contemplates a reconstituted formulation that further comprises a lyoprotectant such as sugars.
  • a lyoprotectant such as sugars.
  • the lyoprotectant sugar can be, for example, sucrose or trehalose, and may be present in an amount of about 60-300 mM.
  • the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
  • the invention provides a formulation containing high concentrations of rhuMAbE-25, rhuMAbE-26 or rhuMAbE-27 as set out in the claims. These antibodies are described in WO 99/1556 .
  • the formulations of the present invention may be pharmaceutical formulations, in particular, formulations for subcutaneous administration.
  • the present invention provides a method of reducing the kinematic viscosity of a formulation containing an immunoglobulin in an amount of at least 80 mg/ml, comprising the addition of a salt and/or buffer in an amount of at least 100 mM, wherein the immunoglobulin is the antibody rhuMAb-E25, rhuMAb-E26, or rhuMAb-E27, and wherein said salt is not sodium chloride, as set out in the claims.
  • the viscosity is reduced to 50 mm2/s or less at 25°C. In a specific aspect, the viscosity is reduced to about 2 to 30 mm 2 /s.
  • the salts or buffer components may be added in an amount of at least about 100 mM, preferably about 100-200 mM, most preferably about 150 mM.
  • the salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with "base forming" metals or amines. Alternatively, the salts and/or buffers may be derived from amino acids. In yet another specific aspect, the salts and/or buffers are monovalent. In yet another specific aspect, the salts are selected from the group consisting of arginine hydrochloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, zinc chloride and sodium acetate.
  • the formulation contains the above salt or buffer components in an amount of about 100-200 mM, and has a viscosity of about 2 to 30 mm 2 /s.
  • the immunoglobulin in the formulation has a molecular weight of at least about 15-20 kD.
  • the formulation may further comprise a surfactant such as polysorbate.
  • the invention also contemplates a reconstituted formulation that further comprises a lyoprotectant such a sugar.
  • the lyoprotectant sugar can be, for example, sucrose or trehalose, and may be present in an amount of about 60-300 mM.
  • the formulation can be reconstituted with a diluent comprising the buffer or salt.
  • the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
  • the invention provides a method of reducing the viscosity of an immunoglobulin formulation as set out in the claims.
  • the method is used to prepare a reconstitutable formulation, specially those that are concentrated to a much greater concentration of immunoglobulin ( e.g. , 2-40 times) after the concentration step (e.g. , lyophilization) compared to before.
  • Such formulations are particularly useful for subcutaneous administration.
  • Also described herein is a method of preventing self-association of proteins in concentrated liquid formulations by (1) adding a salt or a buffer component in an amount of at least about 50 mM; or (2) altering the pH by lowering to ( ⁇ 4.0 to ⁇ 5.3) or elevating to ( ⁇ 6.5 to ⁇ 12.0).
  • the self-association to be prevented is that induced or exacerbated by the presence of sugars (e.g. , sucrose or trehalose) that are commonly used as lyoprotectants. Accordingly, this method is particularly useful for preventing self-association of reconstituted lyophilized formulations.
  • proteins are distinguished from “peptides” which are also amino acid - based molecules that do not have such structure.
  • an immunoglobulin for use herein will have a molecular weight of at least about 15-20 kD, preferably at least about 20 kD.
  • proteins include mammalian proteins, such as, e.g. , growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; ⁇ -1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or tissue-type plasminogen activator (t-PA, e.g.
  • ILs interleukins
  • IL-1 interleukins
  • superoxide dismutase superoxide dismutase
  • T-cell receptors surface membrane proteins
  • DAF decay accelerating factor
  • a viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; immunoadhesins; antibodies; and biologically active fragments or variants of any of the above-listed polypeptides.
  • the immunoglobulin which is formulated is preferably essentially pure and desirably essentially homogeneous (i.e . free from contaminating proteins).
  • Essentially pure protein means a composition comprising at least about 90% by weight of the protein, based on total weight of the composition, preferably at least about 95% by weight.
  • Essentially homogeneous protein means a composition comprising at least about 99% by weight of protein, based on total weight of the composition.
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments ( e.g. , Fab, F(ab') 2 , and Fv).
  • the basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains.
  • An IgM antibody consists of 5 of the basic heterotetramer unit along with an additional polypeptide called a J chain, and contains 10 antigen binding sites, while IgA antibodies comprise from 2-5 of the basic 4-chain units which can polymerize to form polyvalent assemblages in combination with the J chain.
  • the 4-chain unit is generally about 150,000 daltons.
  • Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype.
  • Each H and L chain also has regularly spaced intrachain disulfide bridges.
  • Each H chain has at the N-terminus, a variable domain (V H ) followed by three constant domains (C H ) for each of the ⁇ and ⁇ chains and four C H domains for ⁇ and ⁇ isotypes.
  • Each L chain has at the N-terminus, a variable domain (V L ) followed by a constant domain at its other end.
  • the V L is aligned with the V H and the C L is aligned with the first constant domain of the heavy chain (C H 1). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains.
  • the pairing of a V H and V L together forms a single antigen-binding site.
  • immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, having heavy chains designated ⁇ , ⁇ , ⁇ , ⁇ ank ⁇ , respectively.
  • the ⁇ and ⁇ classes are further divided into subclasses on the basis of relatively minor differences in the CH sequence and function, e.g. , humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
  • variable refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies.
  • the V domain mediates antigen binding and defines the specificity of a particular antibody for its particular antigen.
  • variability is not evenly distributed across the entire span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of about 15-30 amino acid residues separated by shorter regions of extreme variability called “hypervariable regions” or sometimes “complementarity determining regions” (CDRs) that are each approximately 9-12 amino acid residues in length.
  • FRs framework regions
  • hypervariable regions or sometimes “complementarity determining regions”
  • variable domains of native heavy and light chains each comprise four FRs, largely adopting a ⁇ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991 ).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody dependent cellular cytotoxicity (ADCC).
  • ADCC antibody dependent cellular cytotoxicity
  • hypervariable region also known as “complementarity determining regions” or CDRs
  • CDRs complementarity determining regions
  • two residue identification techniques define regions of overlapping, but not identical regions, they can be combined to define a hybrid CDR.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e ., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256: 495 (1975 ), or may be made by recombinant DNA methods (see, e.g. , U.S. Patent No. 4,816,567 ).
  • the "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991 ) and Marks et al., J. Mol. Biol., 222:581-597 (1991 ), for example.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity ( U.S. Patent No. 4,816,567 ; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984 )).
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homo
  • an “intact” antibody is one which comprises an antigen-binding site as well as a CL and at least the heavy chain domains, C H 1, C H 2 and C H 3.
  • antibody fragment comprises a portion of an intact antibody, preferably the antigen binding and/or the variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab') 2 and Fv fragments; diabodies; linear antibodies (see U.S. Patent 5,641,870 , Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995] ); single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produced two identical antigen-binding fragments, called “Fab” fragments, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
  • the Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V H ), and the first constant domain of one heavy chain (C H 1).
  • Each Fab fragment is monovalent with respect to antigen binding, i.e. , it has a single antigen-binding site.
  • Pepsin treatment of an antibody yields a single large F(ab') 2 fragment which roughly corresponds to two disulfide linked Fab fragments having different antigen-binding activity and is still capable of cross-linking antigen.
  • Fab' fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of the C H 1 domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides.
  • the effector functions of antibodies are determined by sequences in the Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of cells.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervarible loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • Single-chain Fv also abbreviated as “sFv” or “scFv” are antibody fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain.
  • the sFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10) residues) between the V H and V L domains such that inter-chain but not intra-chain pairing of the V domains is achieved, thereby resulting in a bivalent fragment, i.e ., a fragment having two antigen-binding sites.
  • Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the V H and V L domains of the two antibodies are present on different polypeptide chains.
  • Diabodies are described in greater detail in, for example, EP 404,097 ; WO 93/11161 ; Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993 ).
  • An antibody that "specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
  • Humanized forms of non-human (e.g. , murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) of mostly human sequences, which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (also CDR) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • "humanized antibodies” as used herein may also comprise residues which are found neither in the recipient antibody nor the donor antibody. These modifications are made to further refine and optimize antibody performance.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Antibody effector functions refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors ( e.g. , B cell receptors); and B cell activation.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FcRs Fc receptors
  • cytotoxic cells e.g. , natural killer (NK) cells, neutrophils and macrophages
  • NK cells natural killer cells
  • neutrophils and macrophages enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins.
  • the antibodies “arm" the cytotoxic cells and are required for killing of the target cell by this mechanism.
  • the primary cells for mediating ADCC, NK cells express Fc ⁇ RIII only, whereas monocytes express Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII.
  • Fc expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-92 (1991 ).
  • an in vitro ACDD assay such as that described in U.S. Patent No. 5,500,362 or 5,821,337 may be performed.
  • Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells.
  • PBMC peripheral blood mononuclear cells
  • NK natural killer
  • ADCC activity of the molecule of interest may be assessed in vivo , e.g. , in an animal model such as that disclosed in Clynes et al., PNAS USA 95:652-656 (1998 ).
  • Fc receptor or “FcR” describes a receptor that binds to the Fc region of an antibody.
  • the preferred FcR is a native sequence human FcR.
  • a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fcc ⁇ I, Fc ⁇ RII, and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors, Fc ⁇ RII receptors include Fc ⁇ RIIA (an “activating receptor”) and Fc ⁇ RIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof.
  • Activating receptor Fc ⁇ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain.
  • Inhibiting receptor Fc ⁇ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain.
  • ITAM immunoreceptor tyrosine-based activation motif
  • ITIM immunoreceptor tyrosine-based inhibition motif
  • FcR FcR
  • the term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus. Guyer et al., J. Immunol. 117: 587 (1976 ) and Kim et al., J. Immunol. 24: 249 (1994 ).
  • Human effector cells are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least Fc ⁇ RIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils, with PBMCs and MNK cells being preferred.
  • PBMC peripheral blood mononuclear cells
  • NK natural killer cells
  • monocytes cytotoxic T cells and neutrophils
  • the effector cells may be isolated from a native source, e.g. , blood.
  • “Complement dependent cytotoxicity” of “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen.
  • C1q first component of the complement system
  • a CDC assay e.g. , as described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996 ), may be performed.
  • a “stable” formulation is one in which the protein therein essentially retains its physical and chemical stability and integrity upon storage.
  • Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, New York, Pubs. (1991 ) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993 ).
  • Stability can be measured at a selected temperature for a selected time period. For rapid screening, the formulation may be kept at 40°C for 2 weeks to 1 month, at which time stability is measured.
  • the formulation should be stable at 30°C or 40°C for at least 1 month and/or stable at 2-8°C for at least 2 years.
  • the formulation should be stable for at least 2 years at 30°C and/or stable at 40°C for at least 6 months.
  • the extent of aggregation following lyophilization and storage can be used as an indicator of protein stability.
  • a "stable" formulation may be one wherein less than about 10% and preferably less than about 5% of the protein are present as an aggregate in the formulation. In other embodiments, any increase in aggregate formation following lyophilization and storage of the lyophilized formulation can be determined.
  • a “stable" lyophilized formulation may be one wherein the increase in aggregate in the lyophilized formulation is less than about 5% and preferably less than about 3%, when the lyophilized formulation is stored at 2-8°C for at least one year.
  • stability of the protein formulation may be measured using a biological activity assay.
  • a "reconstituted" formulation is one which has been prepared by dissolving a lyophilized protein formulations in a diluent such that the protein is dispersed in the reconstituted formulation.
  • the reconstituted formulation is suitable for administration (e.g . parenteral administration) to a patient to be treated with the immunoglobulin of interest and, in certain embodiments of the invention, may be one which is suitable for subcutaneous administration.
  • An "isotonic" formulation is one which has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 250 to 350 mOsm.
  • the term “hypotonic” describes a formulation with an osmotic pressure below that of human blood.
  • the term “hypertonic” is used to describe a formulation with an osmotic pressure above that of human blood. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
  • the formulations of the present invention are hypertonic as a result of the addition of salt and/or buffer.
  • a “pharmaceutically acceptable acid” includes inorganic and organic acids which are non toxic at the concentration and manner in which they are formulated.
  • suitable inorganic acids include hydrochloric, perchloric, hydrobromic, hydroiodic, nitric, sulfuric, sulfonic, sulfinic, sulfanilic, phosphoric, carbonic, etc .
  • Suitable organic acids include straight and branched-chain alkyl, aromatic, cyclic, cyloaliphatic, arylaliphatic, heterocyclic, saturated, unsaturated, mono, di- and tri-carboxylic, including for example, formic, acetic, 2-hydroxyacetic, trifluoroacetic, phenylacetic, trimethylacetic, t-butyl acetic, anthranilic, propanoic, 2-hydroxypropanoic, 2-oxopropanoic, propandioic, cyclopentane-propionic, cyclopentane propionic, 3-phenylpropionic, butanoic, butandioic, benzoic, 3-(4-hydroxybenzoyl)benzoic, 2-acetoxy-benzoic, ascorbic, cinnamic, lauryl sulfuric, stearic, muconic, mandelic, succinic, embonic, fumaric, malic, maleic, hydroxymale
  • “Pharmaceutically-acceptable bases” include inorganic and organic bases were are non-toxic at the concentration and manner in which they are formulated.
  • suitable bases include those formed from inorganic base forming metals such as lithium, sodium, potassium, magnesium, calcium, ammonium, iron, zinc, copper, manganese, aluminum, N-methylglucamine, morpholine, piperidine and organic nontoxic bases including, primary, secondary and tertiary amine, substituted amines, cyclic amines and basic ion exchange resins, [ e.g. , N(R') 4 + (where R' is independently H or C 1-4 alkyl, e.g.
  • ammonium, Tris for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
  • Additional pharmaceutically acceptable acids and bases useable with the present invention include those which are derived from the amino acids, for example, histidine, glycine, phenylalanine, aspartic acid, glutamic acid, lysine and asparagine.
  • “Pharmaceutically acceptable” buffers and salts include those derived from both acid and base addition salts of the above indicated acids and bases. Specific buffers and or salts include histidine, succinate and acetate.
  • a “lyoprotectant” is a molecule which, when combined with a protein of interest, significantly prevents or reduces chemical and/or physical instability of the protein upon lyophilization and subsequent storage.
  • exemplary lyoprotectants include sugars and their corresponding sugar alchohols; an amino acid such as monosodium glutamate or histidine; a methylamine such as betaine; a lyotropic salt such as magnesium sulfate; a polyol such as trihydric or higher molecular weight sugar alcohols, e.g .
  • glycerin dextran, erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol; propylene glycol; polyethylene glycol; Pluronics®; and combinations thereof.
  • Additional exemplary lyoprotectants include glycerin and gelatin, and the sugars mellibiose, melezitose, raffinose, mannotriose and stachyose.
  • reducing sugars include glucose, maltose, lactose, maltulose, iso-maltulose and lactulose.
  • non-reducing sugars include non-reducing glycosides of polyhydroxy compounds selected from sugar alcohols and other straight chain polyalcohols.
  • Preferred sugar alcohols are monoglycosides, especially those compounds obtained by reduction of disaccharides such as lactose, maltose, lactulose and maltulose.
  • the glycosidic side group can be either glucosidic or galactosidic.
  • Additional examples of sugar alcohols are glucitol, maltitol, lactitol and iso-maltulose.
  • the preferred lyoprotectant are the non-reducing sugars trehalose or sucrose.
  • the lyoprotectant is added to the pre-lyophilized formulation in a "lyoprotecting amount" which means that, following lyophilization of the protein in the presence of the lyoprotecting amount of the lyoprotectant, the protein essentially retains its physical and chemical stability and integrity upon lyophilization and storage.
  • diluent of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation, such as a formulation reconstituted after lyophilization.
  • exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • BWFI bacteriostatic water for injection
  • pH buffered solution e.g. phosphate-buffered saline
  • sterile saline solution e.g. phosphate-buffered saline
  • Ringer's solution or dextrose solution e.g. phosphate-buffered saline
  • diluents can include aqueous solutions of salts and/or buffers.
  • a "preservative" is a compound which can be added to the formulations herein to reduce bacterial action.
  • the addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
  • potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride.
  • preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m -cresol.
  • aromatic alcohols such as phenol, butyl and benzyl alcohol
  • alkyl parabens such as methyl or propyl paraben
  • catechol resorcinol
  • cyclohexanol 3-pentanol
  • m -cresol m -cresol
  • a “bulking agent” is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (e.g . facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure).
  • Exemplary bulking agents include mannitol, glycine, polyethylene glycol and sorbitol.
  • the liquid formulations of the present invention obtained by reconstitution of a lyophilized formulation may contain such bulking agents.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, mice, cats, etc .
  • the mammal is human.
  • a “disorder” is any condition that would benefit from treatment with the protein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
  • disorders to be treated herein include carcinomas and allergies.
  • a “therapeutically effective amount” is at least the minimum concentration required to effect a measurable improvement or prevention of a particular disorder.
  • Therapeutically effective amounts of known proteins are well known in the art, while the effective amounts of proteins hereinafter discovered may be determined by standard techniques which are well within the skill of a skilled artisan, such as an ordinary physician.
  • Viscosity as used herein may be “kinematic viscosity” or “absolute viscosity.” "Kinematic viscosity” is a measure of the resistive flow of a fluid under the influence of gravity. When two fluids of equal volume are placed in identical capillary viscometers and allowed to flow by gravity, a viscous fluid takes longer than a less viscous fluid to flow through the capillary. If one fluid takes 200 seconds to complete its flow and another fluid takes 400 seconds, the second fluid is twice as viscous as the first on a kinematic viscosity scale.
  • Absolute Viscosity Kinematic Viscosity ⁇ Density
  • the dimension of kinematic viscosity is L 2 /T where L is a length and T is a time. Commonly, kinematic viscosity is expressed in centistokes (cSt).
  • the SI unit of kinematic viscosity is mm 2 /s, which is 1 cSt. Absolute viscosity is expressed in units of centipoise (cP).
  • the immunoglobulin protein to be formulated may be produced by any known technique, such as by culturing cells transformed or transfected with a vector containing nucleic acid encoding the protein, as is well known in art, or through synthetic techniques (such as recombinant techniques and peptide synthesis or a combination of these techniques) or may be isolated from an endogenous source of the protein.
  • Preparation of the immunoglobulin protein to be formulated by the method of the invention by recombinant means may be accomplished by transfecting or transforming suitable host cells with expression or cloning vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • the culture conditions such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: A Practical Approach, M. Butter, Ed.
  • the nucleic acid encoding the desired immunoglobulin protein for formulation according to the present method may be inserted into a replicable vector for cloning or expression.
  • Suitable vectors are publicly available and may take the form of a plasmid, cosmid, viral particle or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, and enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
  • Forms of immunoglobulin the protein to be formulated may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent or through enzymatic cleavage. Cells employed for expression can also be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption or cell lysing agents.
  • Purification of the immunoglobulin protein to be formulated may be effected by any suitable technique known in the art, such as for example, fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica or cation-exchange resin (e.g. , DEAE), chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, gel filtration using protein A Sepharose columns (e.g. , Sephadex® G-75) to remove contaminants such as IgG, and metal chelating columns to bind epitope-tagged forms.
  • any suitable technique known in the art such as for example, fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica or cation-exchange resin (e.g. , DEAE), chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, gel filtration using protein A Sepharose columns (e.g. , Sephadex
  • Polyclonal antibodies are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g. , keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor.
  • a protein that is immunogenic in the species to be immunized e.g. , keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor.
  • adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
  • the immunization protocol may be selected by one skilled in the art without undue experimentation.
  • the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.
  • the monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975 ), or may be made by recombinant DNA methods ( U.S. Patent No. 4,816,567 ).
  • a mouse or other appropriate host animal such as a hamster
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell ( Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986 ).
  • the immunizing agent will typically include the protein to be formulated. Generally either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • PBLs peripheral blood lymphocytes
  • the lymphoctyes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
  • a suitable fusing agent such as polyethylene glycol
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies ( Kozbor, J. Immunol., 133:3001 (1984 ); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987 )).
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980 ).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra ). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the immunizing agent will typically include the epitope protein to which the antibody binds.
  • PBLs peripheral blood lymphocytes
  • spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
  • a suitable fusing agent such as polyethylene glycol
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myelome cell lines are employed.
  • the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT)
  • HGPRT or HPRT hypoxanthine guanine phosphoribosyl transferase
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. Kozbor, J. Immunol., 133:3001 (1984 ); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63 .
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the protein to be formulated.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980 ).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, supra. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g. , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • antibodies can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990 ). Clackson et al., Nature, 352:624-628 (1991 ) and Marks et al., J. Mol. Biol., 222:581-597 (1991 ) describe the isolation of murine and human antibodies, respectively, using phage libraries.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences ( U.S. Patent No. 4,816,567 ; Morrison, et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984 )), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
  • Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond.
  • suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
  • the antibodies subject to the formulation method may further comprise humanized or human antibodies.
  • Humanized forms of non-human (e.g. , murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementarity determining region
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domain, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers, Jones et al., Nature 321:522-525 (1986 ); Riechmann et al., Nature 332:323-327 (1988 ); Verhoeyen et al., Science 239:1534-1536 (1988 ), or through substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies ( U.S. Patent No. 4,816,567 ), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
  • the human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody.
  • FR human framework
  • Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies. Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992 ); Presta et al., J. Immnol., 151:2623 (1993 ).
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
  • Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e. , the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding.
  • transgenic animals e.g. , mice
  • transgenic animals e.g. , mice
  • J H antibody heavy-chain joining region
  • transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g. , Jakobovits et al., Proc. Natl. Acad. Sci.
  • Human antibodies can also be derived from phage-display libraries ( Hoogenboom et al., J. Mol. Biol., 227:381 (1991 ); Marks et al., J. Mol. Biol., 222:581-597 (1991 )).
  • Human antibodies can also be produced using various techniques known in the art, including phage display libraries. Hoogenboom and Winter, J. Mol. Biol. 227:381 (1991 ); Marks et al., J. Mol. Biol. 222: 581 (1991 ). The techniques of Cole et al. , and Boerner et al. , are also available for the preparation of human monoclonal antibodies ( Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985 ) and Boerner et al., J. Immunol. 147(1): 86-95 (1991 ).
  • human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g. , mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resemble that seen in human in all respects, including gene rearrangement, assembly and antibody repertoire. This approach is described, for example, in U.S. Patent Nos.
  • ADPT Antibody Dependent Enzyme-Mediated Prodrug Therapy
  • the antibodies of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g . a peptidyl chemotherapeutic agent, see WO 81/01145 ) to an active anti-cancer drug.
  • a prodrug e.g . a peptidyl chemotherapeutic agent, see WO 81/01145
  • an active anti-cancer drug See, for example, WO 88/07378 and U. S. Patent No. 4,975,278 .
  • the enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such as way so as to convert it into its more active, cytotoxic form.
  • Enzymes that are useful in the method of this invention include, but are not limited to, glycosidase, glucose oxidase, human lysozyme, human glucuronidase, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases ( e.g.
  • carboxypeptidase G2 and carboxypeptidase A) and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs
  • D-alanylcarboxypeptidases useful for converting prodrugs that contain D-amino acid substituents
  • carbohydrate-cleaving enzymes such as ⁇ -galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs
  • ⁇ -lactamase useful for converting drugs derivatized with ⁇ -lactams into free drugs
  • penicillin amidases such as penicillin Vamidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs.
  • antibodies with enzymatic activity can be used to convert the prodrugs of the invention into free active drugs (see, e.g. , Massey, Nature 328: 457-458 (1987 )).
  • Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.
  • the enzymes of this invention can be covalently bound to the anti-IL-17 or anti-LIF antibodies by techniques well known in the art such as the use of the heterobifunctional cross-linking agents discussed above.
  • fusion proteins comprising at least the antigen binding region of the antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g . Neuberger et al., Nature 312: 604-608 (1984 )).
  • Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Such antibodies can be derived from full length antibodies or antibody fragments ( e.g . F(ab') 2 bispecific antibodies).
  • bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities. Millstein et al., Nature, 305:537-539 (1983 ). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829 and in Traunecker et al., EMBO J., 10:3655-3659 (1991 ).
  • Antibody variable domains with the desired binding specificities can be fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions.
  • DNAs encoding the immunoglobulin heavy-chain fusions, and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
  • antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions.
  • DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. , tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chains(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones ( e.g. , alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690, published March 3, 1994 . For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986 ).
  • Bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
  • one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
  • Such antibodies have, for example, been proposed to target immune system cells to unwanted cells ( US Patent No. 4,676,980 ), and for treatment of HIV infection ( WO 91/00360 , WO 92/200373 ).
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980 , along with a number of cross-linking techniques.
  • bispecific antibodies from antibody fragments
  • the following techniques can also be used for the production of bivalent antibody fragments which are not necessarily bispecific.
  • Fab' fragments recovered from E. coli can be chemically coupled in vitro to form bivalent antibodies. See, Shalaby et al., J. Exp. Med., 175:217-225 (1992 ).
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229: 81 (1985 ) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • Fab' fragments may be directly recovered from E. coli and chemically coupled to form bispecific antibodies.
  • Shalaby et al., J. Exp. Med. 175: 217-225 (1992 ) describes the production of fully humanized bispecific antibody F(ab') 2 molecules.
  • Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody.
  • the bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
  • bivalent heterodimers have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers.
  • the "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci.
  • the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • sFv single-chain Fv
  • Antibodies with more than two valencies are contemplated.
  • trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147: 60 (1991 ).
  • bispecific antibodies may bind to two different epitopes on a given molecule.
  • an anti-protein arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. , CD2, CD3, CD28 or B7), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular protein.
  • Bispecific antibocis may also be used to localize cytotoxic agents to cells which express a particular protein.
  • Such antibodies possess a protein-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA or TETA.
  • a cytotoxic agent or a radionuclide chelator such as EOTUBE, DPTA, DOTA or TETA.
  • Another bispecific antibody of interest binds the protein of interest and further binds tissue factor (TF).
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example; been proposed to tatget immune system cells to unwanted cells, U.S.P. 4,676,980 , and for treatment of HIV infection. WO 91/00360 , WO 92/200373 and EP 03089 . It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980 .
  • the formulations herein are not limited to reconstituted lyophilized formulations
  • the immunoglobulin proteins are lyophilized and then reconstituted to produce the reduced-viscosity stable liquid formulations of the invention.
  • a "pre-lyophilized formulation” is produced after preparation of the immunoglobulin protein of interest as described above.
  • the amount of immunoglobulin protein present in the pre-lyophilized formulation is determined taking into account the desired dose volumes, mode(s) of administration etc.
  • the starting concentration of an intact antibody can be from about 2 mg/ml to about 50 mg/ml, preferably from about 5 mg/ml to about 40 mg/ml and most preferably from about 20-30 mg/ml.
  • the immunoglobulin protein to be formulated is generally present in solution.
  • the protein in the elevated ionic strength reduced viscosity formulations of the invention, the protein may be present in a pH-buffered solution at a pH from about 4-8, and.preferably from about 5-7.
  • the buffer concentration can be from about 1 mM to about 20 mM, alternatively from about 3 mM to about 15 mM, depending, for example, on the buffer and the desired tonicity of the formulation (e.g. of the reconstituted formulation).
  • Exemplary buffers and/or salts are those which are pharmaceutically acceptable and may be created from suitable acids, bases and salts thereof, such as those which are defined under "pharmaceutically acceptable" acids, bases or buffers.
  • a lyoprotectant is added to the pre-lyophilized formulation.
  • the amount of lyoprotectant in the pre-lyophilized formulation is generally such that, upon reconstitution, the resulting formulation will be isotonic. However, hypertonic reconstituted formulations may also be suitable.
  • the amount of lyoprotectant must not be too low such that an unacceptable amount of degradation/aggregation of the protein occurs upon lyophilization.
  • exemplary lyoprotectant concentrations in the pre-lyophilized formulation are from about 10 mM to about 400 mM, alternatively from about 30 mM to about 300 mM, alternatively from about 50 mM to about 100 mM.
  • lyoprotectants include sugars and sugar alcohols such as sucrose, mannose, trehalose, glucose, sorbitol, mannitol. However, under particular circumstances, certain lyoprotectants may also contribute to an increase in viscosity of the formulation. As such, care should be taken so as to select particular lyoprotectants which minimize or neutralize this effect. Additional lyoprotectants are described above under the definition of "lyoprotectants”.
  • the ratio of protein to lyoprotectant can vary for each particular immunoglobulin protein or antibody and lyoprotectant combination.
  • the molar ratio of lyoprotectant to antibody may be from about 100 to about 1500 moles lyoprotectant to 1 mole antibody, and preferably from about 200 to about 1000 moles of lyoprotectant to 1 mole antibody, for example from about 200 to about 600 moles of lyoprotectant to 1 mole antibody.
  • a surfactant may be added to the pre-lyophilized formulation.
  • the surfactant may be added to the lyophilized formulation and/or the reconstituted formulation.
  • exemplary surfactants include nonionic surfactants such as polysorbates ( e.g . polysorbates 20 or 80); polyoxamers ( e.g .
  • poloxamer 188 Triton; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine ( e.g .
  • the amount of surfactant added is such that it reduces particulate formation of the reconstituted protein and minimizes the formation of particulates after reconstitution.
  • the surfactant may be present in the pre-lyophilized formulation in an amount from about 0.001-0.5%, alternatively from about 0.005-0.05%.
  • a mixture of the lyoprotectant (such as sucrose or trehalose) and a bulking agent (e.g . mannitol or glycine) may be used in the preparation of the pre-lyophilization formulation.
  • the bulking agent may allow for the production of a uniform lyophilized cake without excessive pockets therein etc .
  • Other pharmaceutically acceptable carriers, excipients or stabilizers such as those described in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980 ) may be included in the pre-lyophilized formulation (and/or the lyophilized formulation and/or the reconstituted formulation) provided that they do not adversely affect the desired characteristics of the formulation.
  • Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include; additional buffering agents; preservatives; co-solvents; antioxidants including ascorbic acid and methionine; chelating agents such as EDTA; metal complexes ( e.g . Zn-protein complexes); biodegradable polymers such as polyesters; and/or salt-forming counterions such as sodium.
  • the formulation herein may also contain more than one immunoglobulin protein as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect the other protein.
  • immunoglobulin protein as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect the other protein.
  • Such proteins are suitably present in combination in amounts that are effective for the purpose intended.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to, or following, lyophilization and reconstitution. Alternatively, sterility of the entire mixture may be accomplished by autoclaving the ingredients, except for protein, at about 120°C for about 30 minutes, for example.
  • the formulation is lyophilized.
  • freeze-dryers are available for this purpose such as Hull50TM (Hull, USA) or GT20TM (Leybold-Heraeus, Germany) freeze-dryers. Freeze-drying is accomplished by freezing the formulation and subsequently subliming ice from the frozen content at a temperature suitable for primary drying. Under this condition, the product temperature is below the eutectic point or the collapse temperature of the formulation.
  • the shelf temperature for the primary drying will range from about -30 to 25°C (provided the product remains frozen during primary drying) at a suitable pressure, ranging typically from about 50 to 250 mTorr.
  • the formulation, size and type of the container holding the sample (e.g. , glass vial) and the volume of liquid will mainly dictate the time required for drying, which can range from a few hours to several days ( e.g . 40-60 hrs).
  • a secondary drying stage may also be performed depending upon the desired residual moisture level in the product.
  • the temperature at which the secondary drying is carried out ranges from about 0-40°C, depending primarily on the type and size of container and the type of protein employed.
  • the shelf temperature throughout the entire water removal phase of lyophilization may be from about 15-30°C ( e.g. , about 20°C).
  • the time and pressure required for secondary drying will be that which produces a suitable lyophilized cake, dependent, e.g.
  • the secondary drying time is dictated by the desired residual moisture level in the product and typically takes at least about 5 hours ( e.g . 10-15 hours).
  • the pressure may be the same as that employed during the primary drying step. Freeze-drying conditions can be varied depending on the formulation and vial size.
  • the lyophilized formulation Prior to administration to the patient, the lyophilized formulation is reconstituted with a pharmaceutically acceptable diluent such that the immunoglobulin protein concentration in the reconstituted formulation is at least about 80 mg/ml, for example from about 80 mg/ml to about 400 mg/ml, alternatively from about 80 mg/ml to about 300 mg/ml, alternatively from about 90 mg/ml to about 150 mg/ml.
  • a pharmaceutically acceptable diluent such that the immunoglobulin protein concentration in the reconstituted formulation is at least about 80 mg/ml, for example from about 80 mg/ml to about 400 mg/ml, alternatively from about 80 mg/ml to about 300 mg/ml, alternatively from about 90 mg/ml to about 150 mg/ml.
  • the protein concentration in the reconstituted formulation is significantly higher than that in the pre-lyophilized formulation.
  • the protein concentration in the reconstituted formulation may be about 2-40 times, alternatively 3-10 times, alternatively 3-6 times (
  • Reconstitution generally takes place at a temperature of about 25°C to ensure complete hydration, although other temperatures may be employed as desired.
  • the time required for reconstitution will depend, e.g. , on the type of diluent, amount of excipient(s) and protein.
  • Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g . phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • BWFI bacteriostatic water for injection
  • pH buffered solution e.g phosphate-buffered saline
  • sterile saline solution e.g phosphate-buffered saline
  • Ringer's solution or dextrose solution e.g. phosphate-buffered saline
  • the diluent optionally contains a preservative. Exemplary preservative
  • the amount of preservative employed is determined by assessing different preservative concentrations for compatibility with the protein and preservative efficacy testing. For example, if the preservative is an aromatic alcohol (such as benzyl alcohol), it can be present in an amount from about 0. 1-2.0% and preferably from about 0.5-1.5%, but most preferably about 1.0-1.2%.
  • aromatic alcohol such as benzyl alcohol
  • the reconstituted formulation has less than 6000 particles per vial which are ⁇ 10 ⁇ m in size.
  • the formulations of the present invention may be administered to a mammal in need of treatment with the immunoglobulin protein, preferably a human, in accord with known methods, such as intravenous administration as a bolus.or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • the formulations may be administered to the mammal by subcutaneous (i.e . bencath the skin) administration.
  • the formulation may be injected using a syringe.
  • other devices for administration of the formulation are available such as injection devices (e.g . the Inject-easeTM and GenjectTM devices); injector pens (such as the GenPenTM), needleless devices (e.g . MediJectorTM and BioJectorTM); and subcutaneous patch delivery systems.
  • the appropriate dosage ("therapeutically effective amount") of the immunoglobulin protein will depend, for example, on the condition to be treated, the severity and course of the condition, whether the protein is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the protein, the type of protein used, and the discretion of the attending physician.
  • the immunoglobulin protein is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards.
  • the immunoglobulin protein may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
  • the immunoglobulin protein of choice is an antibody
  • from about 0.1-20 mg/kg is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques.
  • an anti-IgE formulation e.g. , rhuMAbE-25, rhMAbE-26
  • a therapeutically effective amount e.g . from about 1-15 mg/kg
  • a therapeutically effective amount e.g . from about 1-15 mg/kg
  • an article of manufacture which contains the formulation as defined in the claims and preferably provides instructions for its use.
  • the article of manufacture comprises a container. Suitable containers include, for example, bottles, vials ( e.g . dual chamber vials), syringes (such as dual chamber syringes) and test tubes.
  • the container may be formed from a variety of materials such as glass or plastic.
  • the container holds the formulation as defined in the claims and the label on, or associated with, the container may indicate directions for use.
  • the label may further indicate that the formulation is useful or intended for subcutaneous administration.
  • the container holding the formulation may be a multi-use vial, which allows for repeat administrations ( e.g. from 2-6 administrations) of the formulation.
  • the article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • rhuMAb E25 a recombinant anti-IgE monoclonal antibody formulation
  • This antibody is a humanized anti-IgE monoclonal antibody that has been developed by Genentech Inc. as a potential therapeutic agent to treat allergic rhinitis and allergic asthma ( Presta et al., J. Immunol. 151(5): 2623-2632 (1993 )( PCT/US92/06860 ).
  • the formulated rhuMAb E25 was formulated to a final concentration of 40 mg/ml, 85 mM Sucrose, 5mM Histidine, 0.01% Polysorbate 20 and filled into 5 cc vials.
  • the samples were then frozen from 5°C to -50°C in 45 minutes and followed by a sequencial increase in the lyophilizer shelf temperature 10°C per hour from -50°C to 25°C.
  • a drying step was conducted at a shelf temperature of 25°C and a chamber pressure of 50 mTorr for 39 hours.
  • the lyophilized rhuMAb E25 was reconstituted with SWFI to produce a solution with rhuMAb E25 at 125 mg/ml, 266 mM sucrose, 16 mM histidine, 0.03% polysorbate 20.
  • the viscosity of reconstituted samples were measured in Cannon-Fenske Routine capillary viscometer (Industrial Research Glassware LTD). The samples were measured approximately at 8 ml with a glass pipette and loaded into a capillary viscometer of size 50 for liquid samples with kinematic viscosity ranging from 0.8 to 4 cs or size 200 for those ranging from 20 to 100 cs.
  • the sample temperature was maintained at 25°C in a waterbath with a digitized temperature control system.
  • the viscometer was placed into the holder vertically and inserted into the waterbath that was maintained at a fixed temperature. The efflux time was measured by allowing the liquid sample to flow freely down past marks.
  • the kinematic viscosity of liquid sample in centistokes was calculated by multiplying the efflux time in seconds by the viscometer constants (0.004 for size 50 and 0.015 for size 100).
  • the viscosity of E25 solution is highly dependent on the concentration of protein molecules ( Figure 1 ). It increases exponentially with increase of rhuMAb E25 concentration. At 25°C, the reconstituted rhuMAb E25 at 125 mg/ml is about 80 fold more viscous than water.
  • Example 1 The lyophilized rhuMAb E25 of Example 1 was reconstituted with different concentrations of NaCl solution. The viscosity of reconstituted solution was measured at 25°C in a Cannon-Fenske Routine capillary viscometer using the same method as described in Example 1.
  • rhuMAb E25 The effects of different salts on the viscosity of rhuMAb E25 solution were studied at 25°C.
  • the lyophilized rhuMAb E25 was first reconstituted with SWFI to produce a solution with rhuMAb E25 at 125 mg/ml, 266 mM sucrose, 16 mM histidine, 0.03% Polysorbate 20.
  • the samples were then diluted with 10 mM histidine, 250 mM sucrose, pH 6.0 to a final concentration of 40 mg/ml.
  • Various concentrated salts were then added into solution to bring the final salt concentration ranging from 0 - 200 mM.
  • the viscosity of solution was determined in a Cannon-Fenske Routine capillary viscometer using the same method as described in Example 1.
  • the viscosity of solution containing either histidine or acetate buffers decreases with increasing buffer concentration up to 200 mM.
  • succinate buffer the viscosity of solution decreases only at low buffer concentration ( ⁇ 100 mM), but not at high buffer concentration (>200 mM).
  • Similar results have also been observed in other buffers that contain negatively charged multivalent buffer components, such as phosphate, citrate and carbonate.
  • This example used a second generation of anti-IgE monoclonal antibody, rhuMAb E26.
  • This monoclonal antibody is a homologous to rhuMAb E25 with five amino acid residue differences in CDR I region in the light chain and is described in WO 99/01556 .
  • the recombinant rhuMAb E26 was also expressed in CHO cell line and purified with similar chromatography methods as described above for rhuMAb E25.
  • the samples were formulated into 5 mM histidine and 275 mM sucrose with concentration of rhuMAb E25 at 21 mg/ml.
  • the viscosity of samples was measured at 6°C in a Cannon-Fenske Routine capillary viscometer using the same method as described in Example 1.
  • hypotonic solutions were prepared by adding small amounts of 10% acetic acid or 0.5 M arginine into an unbuffered rhuMAb E25 solution that has been concentrated to ⁇ 130 mg/ml in Milli-Q water. The final concentrations of total buffer and salt were maintained at 17.5 mM. The hypotonic solutions were then mixed with a small volume of 5 M NaCl to produce the isotonic solutions with final NaCl concentration around 150 mM NaCl.
  • the viscosity of solution was determined at 25°C in a Cannon-Fenske Routine capillary viscometer using the same method as described in Example 1. As shown in figure 6 , the viscosity of rhuMAb E25 solution is highly dependent on the pH of buffer, especially in very hypotonic solutions. The addition of ionic species, such as NaCl, can significantly reduce such pH effects.
  • rhuMAb E25 The effects of pH on viscosity of a reconstituted anti-IgE monoclonal antibody, rhuMAb E25 have also been examined in the presence of other excipients, such as trehalose.
  • the pH of solution was adjusted with 1 M NaOH.
  • the viscosity of solution was determined at 25°C in a Cannon-Fenske Routine capillary viscometer using the same method as described in Example 1. The results, as shown in figure 7 , demonstrated that the viscosity of antibody can be significantly altered by pH of solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (25)

  1. Formulation liquide stable comprenant une immunoglobuline en une quantité d'au moins 80 mg/ml et un sel et/ou tampon en une quantité d'au moins 100 mM, et ayant une viscosité cinématique inférieure ou égale à 50 mm2/s à 25°C, où l'immunoglobuline est l'anticorps rhuMAb-E25, rhuMAb-E26 ou rhuMAb-E27, et où ledit sel n'est pas du chlorure de sodium.
  2. Formulation suivant la revendication 1, comprenant :
    (a) lesdits sel et/ou tampon en une quantité de 100 à 200 mM ; ou
    (b) lesdits sel et/ou tampon en une quantité de 200 mM.
  3. Formulation suivant la revendication 1, dans laquelle lesdits sel et/ou tampon sont dérivés :
    (a) d'un acide organique ou inorganique et d'un métal ou d'une amine formant une base ; ou
    (b) d'un acide aminé.
  4. Formulation suivant la revendication 3, dans laquelle :
    (a) le métal formant une base est choisi dans le groupe consistant en les métaux alcalins, les métaux alcalino-terreux, Al, Zn et Fe ; ou
    (b) l'amine formant une base est une amine de formule NR4 +, dans laquelle R représente indépendamment H ou un groupe alkyle en C1 à C4.
  5. Formulation suivant la revendication 1, dans laquelle le sel et/ou tampon est dérivé d'un acide aminé.
  6. Formulation suivant la revendication 1, dans laquelle ledit sel est choisi dans le groupe consistant en le thiocyanate de sodium, le thiocyanate d'ammonium, le sulfate d'ammonium, le chlorure d'ammonium, le chlorure de calcium, le chlorhydrate d'arginine, le chlorure de zinc et l'acétate de sodium.
  7. Formulation suivant la revendication 1, qui :
    (a) a une viscosité cinématique inférieure ou égale à 40 mm2/s à 25°C ; ou
    (b) a une viscosité cinématique inférieure ou égale à 30 mm2/s à 25°C ; ou
    (c) a une viscosité cinématique inférieure ou égale à 20 mm2/s à 25°C ; ou
    (d) a une viscosité cinématique de 10 à 30 mm2/s à 25°C.
  8. Formulation suivant la revendication 1, comprenant en outre un lyoprotecteur.
  9. Formulation suivant la revendication 8, dans laquelle ledit lyoprotecteur est un sucre.
  10. Formulation suivant la revendication 9, dans laquelle ledit sucre est le saccharose ou le tréhalose.
  11. Formulation suivant la revendication 9, comprenant ledit sucre en une quantité de 60 à 300 mM.
  12. Formulation suivant la revendication 1, comprenant en outre un agent tensioactif.
  13. Formulation suivant la revendication 1, qui est hypertonique.
  14. Formulation suivant la revendication 1, qui est une formulation reconstituée.
  15. Formulation suivant la revendication 14, dans laquelle la concentration en protéine immunoglobuline dans la formulation reconstituée est 2 à 40 fois supérieure à la concentration en protéine immunoglobuline dans le mélange avant lyophilisation.
  16. Formulation suivant la revendication 1, qui est une formulation pharmaceutique liquide.
  17. Formulation suivant la revendication 16, qui est destinée à l'administration sous-cutanée.
  18. Méthode pour réduire la viscosité cinématique d'une formulation contenant une immunoglobuline en une quantité d'au moins 80 mg/ml, comprenant l'addition d'un sel et/ou tampon en une quantité d'au moins 100 mM, où l'immunoglobuline est l'anticorps rhuMAb-E25, rhuMAb-E26 ou rhuMAb-E27, et où ledit sel n'est pas du chlorure de sodium.
  19. Méthode suivant la revendication 18, dans laquelle ledit sel est choisi dans le groupe consistant en le thiocyanate de sodium, le thiocyanate d'ammonium, le sulfate d'ammonium, le chlorure d'ammonium, le chlorure de calcium et le chlorhydrate d'arginine.
  20. Méthode suivant la revendication 18, dans laquelle ladite formulation est une formulation reconstituée.
  21. Méthode suivant la revendication 18, dans laquelle la formulation est hypertonique.
  22. Méthode suivant la revendication 20, dans laquelle la concentration en protéine dans ladite formulation reconstituée est 2 à 40 fois supérieure à la concentration en protéine dans le mélange avant lyophilisation.
  23. Méthode suivant la revendication 18, dans laquelle la viscosité cinématique de ladite formulation est réduite à 50 mm2/s ou moins, de la manière déterminée à 25°C.
  24. Article manufacturé comprenant un récipient contenant la formulation de l'une quelconque des revendications 1 à 17.
  25. Article manufacturé suivant la revendication 24, comprenant en outre des directives pour l'administration de ladite formulation.
EP01981824.4A 2000-10-12 2001-10-04 Formulations de proteine concentrees a viscosite reduite Expired - Lifetime EP1324776B2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200130952T SI1324776T2 (en) 2000-10-12 2001-10-04 Concentrated protein formulations with reduced viscosity
EP09010433.2A EP2116265B1 (fr) 2000-10-12 2001-10-04 Formulations de protéines concentrées à viscosité réduite
CY20091101163T CY1110547T1 (el) 2000-10-12 2009-11-10 Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24010700P 2000-10-12 2000-10-12
US240107P 2000-10-12
US29383401P 2001-05-24 2001-05-24
US293834P 2001-05-24
PCT/US2001/042487 WO2002030463A2 (fr) 2000-10-12 2001-10-04 Formulations de proteine concentrees a viscosite reduite

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP09010433.2A Division-Into EP2116265B1 (fr) 2000-10-12 2001-10-04 Formulations de protéines concentrées à viscosité réduite
EP09010433.2A Division EP2116265B1 (fr) 2000-10-12 2001-10-04 Formulations de protéines concentrées à viscosité réduite

Publications (3)

Publication Number Publication Date
EP1324776A2 EP1324776A2 (fr) 2003-07-09
EP1324776B1 EP1324776B1 (fr) 2009-09-16
EP1324776B2 true EP1324776B2 (fr) 2018-03-21

Family

ID=26933147

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01981824.4A Expired - Lifetime EP1324776B2 (fr) 2000-10-12 2001-10-04 Formulations de proteine concentrees a viscosite reduite
EP09010433.2A Expired - Lifetime EP2116265B1 (fr) 2000-10-12 2001-10-04 Formulations de protéines concentrées à viscosité réduite

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP09010433.2A Expired - Lifetime EP2116265B1 (fr) 2000-10-12 2001-10-04 Formulations de protéines concentrées à viscosité réduite

Country Status (14)

Country Link
US (3) US6875432B2 (fr)
EP (2) EP1324776B2 (fr)
JP (2) JP4340062B2 (fr)
AT (1) ATE442862T2 (fr)
AU (2) AU1344102A (fr)
CA (1) CA2423227C (fr)
CY (1) CY1110547T1 (fr)
DE (1) DE60139944D1 (fr)
DK (1) DK1324776T4 (fr)
ES (1) ES2332402T5 (fr)
IL (3) IL155002A0 (fr)
PT (1) PT1324776E (fr)
SI (1) SI1324776T2 (fr)
WO (1) WO2002030463A2 (fr)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
EP2261335B1 (fr) 1998-11-27 2017-06-14 UCB Pharma S.A. Compositions et méthodes pour augmenter la minéralisation des os
NZ529856A (en) * 1999-10-04 2005-09-30 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PT1401498E (pt) * 2001-05-30 2011-11-24 Genentech Inc Anticorpos anti-ngf para o tratamento de vários distúrbios
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1441589B1 (fr) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Formulation pharmaceutique liquide stable d'anticorps igg
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
EP1551875A4 (fr) * 2002-06-21 2006-06-28 Biogen Idec Inc Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2006514954A (ja) * 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物
DK1599222T3 (da) * 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
US20040208870A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
KR101208291B1 (ko) * 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
CA2530285C (fr) * 2003-06-27 2019-12-24 Abgenix, Inc. Anticorps diriges contre les mutants de deletion du recepteur du facteur de croissance epidermique et utilisations correspondantes
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
US7585496B2 (en) * 2003-11-04 2009-09-08 Lek Pharmaceuticals D.D. Stable pharmaceutical composition granulocyte-colony stimulating factor
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2005063291A1 (fr) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha Preparation medicamenteuse aqueuse stable contenant un anticorps
WO2005072772A1 (fr) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
EP2072040B1 (fr) * 2004-05-12 2013-05-01 Baxter International Inc. L'emploi thérapeutique des microsphères d'acide nucléique
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2007537288A (ja) * 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
ES2531155T3 (es) 2004-07-23 2015-03-11 Genentech Inc Cristalización de anticuerpos anti-VEGF
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2598711C (fr) 2005-03-25 2018-05-29 Regeneron Pharmaceuticals, Inc. Formulations d'antagonistes du facteur vegf
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
MX2007014148A (es) 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
CA2610839C (fr) 2005-06-14 2019-06-25 Amgen Inc. Preparations de proteines a tamponnage spontane
TWI480063B (zh) * 2005-11-01 2015-04-11 Wyeth Corp 用於藥物復原或稀釋的氯化鈉溶液
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1988922A4 (fr) * 2006-02-03 2010-06-02 Medimmune Llc Formulations de protéines
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
EP4218801A3 (fr) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
ES2406764T3 (es) 2006-06-16 2013-06-10 Regeneron Pharmaceuticals, Inc. Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
CN101500616A (zh) * 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
AU2007322265B2 (en) 2006-11-07 2013-06-20 Merck Sharp & Dohme Corp. Antagonists of PCSK9
WO2008133647A2 (fr) * 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
EA200970880A1 (ru) * 2007-03-22 2010-02-26 Имклоун Элэлси Стабильные композиции на основе антител
WO2008118970A2 (fr) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
WO2008121616A2 (fr) * 2007-03-30 2008-10-09 Medimmune, Inc. Anticorps présentant des profils de désamidation réduits
EP2146691A2 (fr) * 2007-04-17 2010-01-27 Baxter International Inc. Microparticules d'acide nucléique pour délivrance pulmonaire
US9186323B2 (en) 2007-05-02 2015-11-17 Novo Nordisk Healthcare Ag High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant
EP2144624A1 (fr) * 2007-05-15 2010-01-20 Stryker Corporation Préparations de protéines concentrées de protéines morphogénétiques d'os et procédés d'utilisation correspondant
CN101679509A (zh) 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US8637021B2 (en) * 2007-11-12 2014-01-28 Ares Trading S.A. Formulations for TACI-immunoglobulin fusion proteins
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0821474B8 (pt) 2007-12-28 2021-05-25 Baxalta GmbH formulação farmacêutica líquida estável
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US20110104142A1 (en) * 2008-05-23 2011-05-05 Novo Nordisk Health Care Ag Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
JP5642065B2 (ja) * 2008-05-23 2014-12-17 ノボ ノルディスク ヘルス ケア アーゲー ペグ化されたｇｌａ−ドメイン含有タンパク質を含む低粘度組成物
JP2011526591A (ja) * 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
WO2010048275A2 (fr) 2008-10-21 2010-04-29 Baxter International Inc. Formulations de vwf recombinant lyophilisé
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2430047B1 (fr) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Molécules neutralisantes dirigées contre les virus de la grippe
EP2476446B1 (fr) * 2009-07-01 2018-08-15 Fresenius Medical Care Holdings, Inc. Dispositifs d'administration de médicaments et systèmes et procédés associés
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2013501058A (ja) * 2009-08-04 2013-01-10 ジェネンテック， インコーポレイテッド 低減された粘性を有する濃縮ポリペプチド製剤
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
DK2473528T3 (en) 2009-09-03 2015-03-02 Ablynx Nv Stable formulations of polypeptides and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2773522C (fr) 2009-10-26 2023-04-18 Chugai Seiyaku Kabushiki Kaisha Procede de fabrication d'une immunoglobuline glycosyle
RU2642295C2 (ru) * 2009-10-26 2018-01-24 Дженентек, Инк. АНАЛИЗЫ ОПРЕДЕЛЕНИЯ АНТИТЕЛ, СПЕЦИФИЧНЫХ К ТЕРАПЕВТИЧЕСКИМ АНТИТЕЛАМ ПРОТИВ IgE, И ИХ ПРИМЕНЕНИЕ ПРИ АНАФИЛАКСИИ
EP2538973A2 (fr) * 2010-02-26 2013-01-02 Novo Nordisk A/S Compositions stables contenant des anticorps
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
ES2642512T3 (es) 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
CA2792125C (fr) 2010-03-22 2019-02-12 Genentech, Inc. Compositions et procedes utiles pour stabiliser les formulations contenant des proteines
EP2566510A1 (fr) * 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions et procédés utiles pour la réduction de la viscosité de formulations contenant des protéines
EP2566502A4 (fr) 2010-05-04 2013-10-09 Glaxosmithkline Llc Méthodes de traitement ou de prévention de troubles cardiovasculaires, et de fourniture d'une protection cardiovasculaire
SG185465A1 (en) * 2010-05-14 2012-12-28 Amgen Inc High concentration antibody formulations
CA2800188A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
KR20220070586A (ko) 2010-11-08 2022-05-31 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
ES2601202T3 (es) 2010-11-11 2017-02-14 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-TNT-alfa de alta concentración
CN103298937B (zh) 2010-11-17 2016-05-25 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
MY176600A (en) 2011-01-28 2020-08-18 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to pcsk9
EP2671176B1 (fr) 2011-01-31 2019-01-09 Fresenius Medical Care Holdings, Inc. Prévention de la suradministration de médicament
CN106902406B (zh) 2011-02-08 2019-11-08 弗雷塞尼斯医疗保健控股公司 磁性传感器及相关系统和方法
CA2828000A1 (fr) 2011-03-01 2012-09-07 Amgen Inc. Agents liants bispecifiques
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
EP2694100A4 (fr) * 2011-04-07 2014-10-01 Glaxosmithkline Llc Formulations ayant une viscosité réduite
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2842860A1 (fr) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Proteines se liant a sur dirigees contre erbb3
CA2842432C (fr) 2011-08-04 2022-10-04 Amgen Inc. Procede de traitement de defauts d'espace osseux
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
EA028278B1 (ru) 2011-09-16 2017-10-31 Ридженерон Фармасьютикалз, Инк. СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9)
CN104023743B (zh) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
CN108771655A (zh) * 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
WO2013066866A1 (fr) 2011-10-31 2013-05-10 Genentech, Inc. Formulations d'anticorps
EP2776052B1 (fr) 2011-11-02 2017-06-14 Halscion, Inc. Méthodes et compositions pour le traitement des plaies
EP2776091B1 (fr) 2011-11-07 2021-03-03 Battelle Memorial Institute Procédés pour la délivrance de traitements médicamenteux visqueux
DK2596796T3 (da) * 2011-11-24 2014-01-27 Quimera Ingenieria Biomedica S L Kompleks opnået af hyaluronsyre eller et salt deraf samt chondroitinsulfatblandinger
EP3446707A1 (fr) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Protéines se liant à un substitut
MX354270B (es) 2011-12-28 2018-02-21 Amgen Inc Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
MX357393B (es) 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
US9144646B2 (en) 2012-04-25 2015-09-29 Fresenius Medical Care Holdings, Inc. Vial spiking devices and related assemblies and methods
EP3427721A1 (fr) 2012-05-18 2019-01-16 Genentech, Inc. Formulations d'anticorps monoclonal à concentration élevée
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
CN104520326A (zh) * 2012-06-21 2015-04-15 Ucb医药有限公司 药物制剂
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
FR2994390B1 (fr) * 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
LT2892550T (lt) 2012-09-07 2020-04-10 Coherus Biosciences, Inc. Stabilios adalimumabo vandeninės kompozicijos
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9474803B2 (en) * 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
PL2968434T3 (pl) 2013-03-15 2018-01-31 Shire Viropharma Inc Kompozycje c1-inh do stosowania w zapobieganiu i leczeniu dziedzicznego obrzęku naczynioruchowego (hae)
WO2014141149A1 (fr) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations présentant une viscosité réduite
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
MX363403B (es) 2013-07-04 2019-03-22 Hoffmann La Roche Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
IL312865A (en) * 2013-09-11 2024-07-01 Eagle Biologics Inc Liquid protein formulations containing viscosity reducing agents
MX2016003616A (es) 2013-09-27 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
WO2015073494A1 (fr) 2013-11-12 2015-05-21 Sanofi Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
US11357857B2 (en) * 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
SG11201700284UA (en) 2014-07-18 2017-02-27 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016019969A1 (fr) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Anticorps bispécifiques administrés par voie sous-cutanée, destinés à être utilisés dans le traitement du cancer
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
CA2962768C (fr) 2014-10-01 2023-10-10 Alyssa M. Larson Formulations de polysaccharides et d'acides nucleiques contenant des agents reducteurs de viscosite
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
SG11201702177VA (en) * 2014-10-18 2017-04-27 Pfizer Anti-il-7r antibody compositions
CA2960797A1 (fr) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Variants du fragment fc caracterises par une liaison fcrn modifiee et leurs procedes d'utilisation
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
GB2556002B (en) * 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
JP2018521129A (ja) * 2015-07-07 2018-08-02 ナノビオ コーポレイションＮａｎｏｂｉｏ Ｃｏｒｐｏｒａｔｉｏｎ タンパク質の安定化のための方法および組成物
US20170007690A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of anthrax recombinant protective antigen
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
WO2017075252A1 (fr) 2015-10-30 2017-05-04 Genentech, Inc. Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
MX2018012648A (es) 2016-04-28 2019-01-30 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos.
EP3254671B1 (fr) 2016-06-10 2019-11-13 Octapharma AG Composition d'immunoglobuline à concentration élevée pour application pharmaceutique
EP3493832A1 (fr) 2016-08-05 2019-06-12 CSL Behring GmbH Formulations pharmaceutiques de l'inhibiteur d'estérase c1
EP4183414A1 (fr) 2016-08-16 2023-05-24 Regeneron Pharmaceuticals, Inc. Procédés de quantification d'anticorps individuels à partir d'un mélange
CA3035327A1 (fr) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Procedes d'utilisation d'un anticorps bispecifique qui reconnait le facteur de coagulation ix et/ou le facteur de coagulation ix active et le facteur de coagulation x et/ou le facteur de coagulation x active
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
IL312194A (en) 2016-10-25 2024-06-01 Regeneron Pharma Methods and systems for analysis of chromatography data
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
BR112020003572A2 (pt) 2017-08-22 2020-08-25 Biogen Ma Inc. composições farmacêuticas contendo anticorpos anti-beta-amiloide
CN118416215A (zh) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
KR20200049764A (ko) 2017-09-29 2020-05-08 추가이 세이야쿠 가부시키가이샤 혈액 응고 제 viii 인자(fviii) 보인자 기능 대체 활성을 갖는 다중특이성 항원 결합 분자 및 당해 분자를 유효 성분으로서 함유하는 약학적 제제
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
WO2019201904A1 (fr) * 2018-04-16 2019-10-24 Merck Patent Gmbh Réduction de la viscosité de formulations de protéines hautement concentrées
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CA3099551A1 (fr) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. Formulations contenant des proteines de fusion du recepteur vegf a haute concentration
EP3818069A1 (fr) 2018-07-02 2021-05-12 Regeneron Pharmaceuticals, Inc. Utilisation d'une chromatographie d'interaction hydrophobe multiple pour préparer un polypeptide à partir d'un mélange
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
IL267923B2 (en) * 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
CA3152838A1 (fr) * 2019-08-30 2021-03-04 Kashiv Biosciences, Llc Nouvelle formulation d'anticorps pharmacologiquement actif hautement concentre
EP3808777A1 (fr) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Formulations d'anticorps liquides stables
US20230279146A1 (en) 2020-07-13 2023-09-07 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
WO2022026699A1 (fr) 2020-07-31 2022-02-03 Genentech, Inc. Formulations d'anticorps anti-intégrine bêta7 et dispositifs
WO2023175035A1 (fr) * 2022-03-15 2023-09-21 Adrenomed Ag Formulation aqueuse stable d'un anticorps anti-adrénomédulline (adm) ou d'un fragment d'anticorps anti-adm
GB202408006D0 (en) 2023-07-28 2024-07-17 Novartis Ag New uses of omalizumab
DE202024000928U1 (de) 2024-05-10 2024-05-16 Genentech, Inc. Omalizumab-Spritze

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004801A1 (fr) † 1995-07-27 1997-02-13 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
WO1999001556A2 (fr) † 1997-07-02 1999-01-14 Genentech, Inc. ANTICORPS ANTI-IgE AMELIORES ET PROCEDE D'AMELIORATION POUR POLYPEPTIDES
WO2002096457A2 (fr) † 2001-05-31 2002-12-05 Novartis Ag Formulations liquides stable s

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55571A (en) * 1866-06-12 Improvement in screw-cutters
US92607A (en) * 1869-07-13 hamilton
CA1064396A (fr) 1975-02-18 1979-10-16 Myer L. Coval Precipitation fractionnee de la gamma globuline a l'aide de polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
AT359641B (de) 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH063994B2 (ja) 1984-10-05 1994-01-12 株式会社日立製作所 複数台デイジタルサーボの制御方法
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4940782A (en) 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0303746B2 (fr) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisation des hormones de croissance
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
CA1331133C (fr) 1988-03-01 1994-08-02 Michael Jon Pikal Formulations pharmaceutiques d'hormone de croissance humaine
US5262296A (en) 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
EP0417193B1 (fr) 1988-05-27 1993-08-04 Centocor, Inc. Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5036050A (en) * 1989-01-12 1991-07-30 Immunobiology Research Institute, Inc. Compositions containing thymopentin for topical treatment of skin disorders
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
ZA902663B (en) 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
KR0149181B1 (ko) 1990-06-29 1998-08-17 데이비드 알, 맥지 형질전환된 미생물에 의한 멜라닌의 제조방법
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
WO1992017207A1 (fr) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES
CA2102511A1 (fr) 1991-05-14 1992-11-15 Paul J. Higgins Anticorps heteroconjugues pour le traitement de l'infection a vih
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
DE69233716T2 (de) 1991-08-14 2008-10-30 Genentech Inc., San Francisco Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
GB9120304D0 (en) 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
CH684164A5 (de) 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE69333928T2 (de) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US5445017A (en) 1993-08-24 1995-08-29 Mita Industrial Co., Ltd. Motor start examining device and method
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US6383788B1 (en) 1994-03-04 2002-05-07 Genentech, Inc. Minimizing thermally induced aggregation of DNase in solution with calcium
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
EP0748326B1 (fr) 1994-12-28 2001-07-04 Rhodia Chimie Diphosphines optiquement actives, leur preparation par dedoublement du melange racemique
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
JP2904071B2 (ja) 1995-10-04 1999-06-14 日本電気株式会社 半導体装置
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0876140B1 (fr) 1996-01-25 2003-10-15 Schering Aktiengesellschaft Solutions d'agents de contraste ameliorees pour administration intraveineuse
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
AU724960C (en) 1996-02-09 2002-08-15 Swedish Orphan Biovitrum Ab (Publ) Composition comprising interleukin-1 inhibitor and controlled release polymer
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US6057505A (en) * 1997-11-21 2000-05-02 Ortabasi; Ugur Space concentrator for advanced solar cells
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
AU6254799A (en) 1998-09-16 2000-04-03 Tanox, Inc. Anti-ige gene therapy
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
NZ529856A (en) 1999-10-04 2005-09-30 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
GB0023383D0 (en) 2000-09-23 2000-11-08 Synprotec Ltd 3,5-Bis (Trifluormethyl)Benzene derivatives
US7335647B2 (en) 2000-10-11 2008-02-26 Kensuke Egashira Drugs for liver diseases
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
EP1441589B1 (fr) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Formulation pharmaceutique liquide stable d'anticorps igg
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004801A1 (fr) † 1995-07-27 1997-02-13 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
WO1999001556A2 (fr) † 1997-07-02 1999-01-14 Genentech, Inc. ANTICORPS ANTI-IgE AMELIORES ET PROCEDE D'AMELIORATION POUR POLYPEPTIDES
WO2002096457A2 (fr) † 2001-05-31 2002-12-05 Novartis Ag Formulations liquides stable s

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADELROTH E. ET AL: "Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.", J. ALLERGY CLIN. IMMUNOL., vol. 106, no. 2, 2000, pages 253 - 259, XP001033936, DOI: doi:10.1067/mai.2000.108310 †
Amended Marketing Authorisation for Xolair (10.02.2009) †
Marketing Authorisation for Xolair (25.10.2005) †

Also Published As

Publication number Publication date
IL231675A (en) 2017-11-30
US7666413B2 (en) 2010-02-23
US20020045571A1 (en) 2002-04-18
JP2009167190A (ja) 2009-07-30
WO2002030463A3 (fr) 2002-10-10
ES2332402T5 (es) 2018-05-14
EP2116265A3 (fr) 2011-08-31
EP2116265A2 (fr) 2009-11-11
JP4340062B2 (ja) 2009-10-07
JP2004532798A (ja) 2004-10-28
ATE442862T2 (de) 2009-10-15
US8142776B2 (en) 2012-03-27
US20050175603A1 (en) 2005-08-11
US20070116700A1 (en) 2007-05-24
PT1324776E (pt) 2009-12-23
CA2423227C (fr) 2011-11-29
EP2116265B1 (fr) 2020-12-23
SI1324776T1 (sl) 2010-01-29
CA2423227A1 (fr) 2002-04-18
DE60139944D1 (de) 2009-10-29
EP1324776A2 (fr) 2003-07-09
WO2002030463A2 (fr) 2002-04-18
DK1324776T3 (da) 2010-01-18
EP1324776B1 (fr) 2009-09-16
IL231675A0 (en) 2014-04-30
US6875432B2 (en) 2005-04-05
CY1110547T1 (el) 2015-04-29
SI1324776T2 (en) 2018-06-29
AU1344102A (en) 2002-04-22
IL155002A0 (en) 2003-10-31
AU2002213441B2 (en) 2006-10-26
IL155002A (en) 2016-09-29
ES2332402T3 (es) 2010-02-04
DK1324776T4 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
US20190231875A1 (en) Reduced-viscosity concentrated protein formulations
EP1324776B2 (fr) Formulations de proteine concentrees a viscosite reduite
AU2002213441A1 (en) Reduced-viscosity concentrated protein formulations
EP2335725B1 (fr) Formulations d'anticorps et de protéines à forte concentration
US6685940B2 (en) Protein formulation
US6821515B1 (en) Protein formulation
EP1516628B1 (fr) Formulation de protéine stabile, lyophilisée et isotonique
US20130058958A1 (en) Compositions and methods useful for reducing the viscosity of protein-containing formulations
CA2751188A1 (fr) Formulations de proteine concentrees a viscosite reduite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030505

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040406

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60139944

Country of ref document: DE

Date of ref document: 20091029

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20091216

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090402724

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2332402

Country of ref document: ES

Kind code of ref document: T3

PLCP Request for limitation filed

Free format text: ORIGINAL CODE: EPIDOSNLIM1

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLCT Request for limitation of patent deemed not filed due to filing of opposition

Free format text: ORIGINAL CODE: 0009234

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Effective date: 20100616

Opponent name: SANOFI-AVENTIS

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: ABLYNX N.V.

Effective date: 20100616

LIM4 Request for limitation deemed not have been filed (opposition pending/filed)

Free format text: SEQUENCE NO: 1; FILED DURING OPPOSITION PERIOD

Filing date: 20100610

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

26 Opposition filed

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Effective date: 20100616

Opponent name: SANOFI-AVENTIS

Effective date: 20100616

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

R26 Opposition filed (corrected)

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: SANOFI-AVENTIS

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: SANOFI-AVENTIS

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: SANOFI

Effective date: 20100616

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: SANOFI

Effective date: 20100616

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: SANOFI

Effective date: 20100616

R26 Opposition filed (corrected)

Opponent name: ABBOTT BIORESEARCH CENTER PATENT DEPARTMENT

Effective date: 20100616

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: SANOFI

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

R26 Opposition filed (corrected)

Opponent name: ARECOR LIMITED

Effective date: 20100615

Opponent name: OCTAPHARMA AG

Effective date: 20100616

Opponent name: ABLYNX N.V.

Effective date: 20100616

Opponent name: DR. MARTIN HUENGES/, DR. LUEDER BEHRENS

Effective date: 20100616

Opponent name: SYNTHON B.V.

Effective date: 20100616

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG/ BOEHRIN

Effective date: 20100616

Opponent name: ABBVIE BIORESEARCH CENTER INC.

Effective date: 20100616

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

Opponent name: BAXTER HEALTHCARE S.A.

Effective date: 20100616

Opponent name: SANOFI

Effective date: 20100616

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: OCTAPHARMA AG

Effective date: 20100616

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: SANOFI

Effective date: 20100616

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: UCB PHARMA S.A.

Effective date: 20100615

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20180321

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 60139944

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AELC

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2332402

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20180514

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20180523

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180401584

Country of ref document: GR

Effective date: 20181031

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20200928

Year of fee payment: 20

Ref country code: PT

Payment date: 20200925

Year of fee payment: 20

Ref country code: FI

Payment date: 20200925

Year of fee payment: 20

Ref country code: GB

Payment date: 20200930

Year of fee payment: 20

Ref country code: DK

Payment date: 20200925

Year of fee payment: 20

Ref country code: GR

Payment date: 20200925

Year of fee payment: 20

Ref country code: FR

Payment date: 20200923

Year of fee payment: 20

Ref country code: NL

Payment date: 20200918

Year of fee payment: 20

Ref country code: LU

Payment date: 20200918

Year of fee payment: 20

Ref country code: IE

Payment date: 20200925

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20200922

Year of fee payment: 20

Ref country code: CH

Payment date: 20200918

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20201001

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200916

Year of fee payment: 20

Ref country code: ES

Payment date: 20201102

Year of fee payment: 20

Ref country code: AT

Payment date: 20200925

Year of fee payment: 20

Ref country code: IT

Payment date: 20201014

Year of fee payment: 20

Ref country code: SE

Payment date: 20201008

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20200922

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60139944

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20211004

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9A

Effective date: 20211004

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20211004

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20211003

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 442862

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211004

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20211003

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20211013

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20211004

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20211003

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 442862

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20211005